Propranolol in Use for Treatment of Complex Infant Hemangiomas: Literature Review Regarding Current Guidelines for Preassessment and Standards of Care before Initiation of Therapy

In 2008, the positive effects of propranolol on infantile hemangiomas (IH) have been discovered serendipitously by Léauté-Labrèze and her coworkers. Since then, propranolol has been in use in allday clinical practice worldwide for treatment of IH. It even caused some kind of paradigm shift in the ov...

Full description

Saved in:
Bibliographic Details
Published in:TheScientificWorld 2013-01, Vol.2013 (2013), p.1-9
Main Author: Fette, Andreas
Format: Article
Language:English
Subjects:
Angiogenesis
Angiogenesis Inhibitors - adverse effects
Angiogenesis Inhibitors - therapeutic use
Antineoplastic Agents - adverse effects
Antineoplastic Agents - therapeutic use
Apoptosis
Cardiac arrhythmia
Cardiovascular disease
Child
Clinical medicine
Clinical trials
Diseases
Dosage and administration
Drug dosages
Drug therapy
Evidence-Based Medicine
Guideline Adherence - utilization
Hemangioma - diagnosis
Hemangioma - drug therapy
Hemangioma - epidemiology
Humans
Infants (Newborn)
Literature reviews
Medical Oncology - standards
Pediatrics - standards
Practice Guidelines as Topic
Propranolol - adverse effects
Propranolol - therapeutic use
Propranolol hydrochloride
Review
Standard of care
Treatment Outcome
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c600t-4847ca3ca12d42e9367901a240bf0a0a4988a701ba6d74fd4e3b67866ae5f0c73
cites cdi_FETCH-LOGICAL-c600t-4847ca3ca12d42e9367901a240bf0a0a4988a701ba6d74fd4e3b67866ae5f0c73
container_end_page 9
container_issue 2013
container_start_page 1
container_title TheScientificWorld
container_volume 2013
creator Fette, Andreas
description In 2008, the positive effects of propranolol on infantile hemangiomas (IH) have been discovered serendipitously by Léauté-Labrèze and her coworkers. Since then, propranolol has been in use in allday clinical practice worldwide for treatment of IH. It even caused some kind of paradigm shift in the overall management of these lesions, though propranolol is still not FDA approved, respectively, in “off-label” use for this indication in the majority of institutions. Thus, the aim of this communication is to evaluate the literature for current evidence regarding guidelines for preassessment and standards of care before initiation of therapy.
doi_str_mv 10.1155/2013/850193
format article
fullrecord <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_81598388037c4c05b55a62604c04a985</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A386341018</galeid><doaj_id>oai_doaj_org_article_81598388037c4c05b55a62604c04a985</doaj_id><sourcerecordid>A386341018</sourcerecordid><originalsourceid>FETCH-LOGICAL-c600t-4847ca3ca12d42e9367901a240bf0a0a4988a701ba6d74fd4e3b67866ae5f0c73</originalsourceid><addsrcrecordid>eNqNkt9rFDEQxxdRbK0--S4LvinX5vfmfBDKoe3BgUWv4FuY3c3u5dhNzmS3tX-X_6Bzd7X2wAcJJGHync93hkyWvabklFIpzxih_ExLQqf8SXZMJS8mhRDfn2bHjEs1UVSQo-xFSmtCuC6ofJ4dMV4ohdfj7NdVDJsIPnShy53Pr5PNmxDzZbQw9NYPeWjyWeg3nf2Zz30DGLm0PfjWhR7Sh3zhBhthGKPNv9obZ2_xaCHWzrf5bIxxi7gYXW07523asa-QnZJNaccHX-ffBtwxKe3cAFmlRaVFRzc4GFzw25flCq02dy-zZw10yb66P0-y68-flrPLyeLLxXx2vphUipBhIrQoKuAVUFYLZqdcFVNCgQlSNgQIiKnWUBBagqoL0dTC8lIVWimwsiFVwU-y-Z5bB1ibTXQ9xDsTwJldIMTWQBxc1VmjqZxqrjXhRSUqIkspQTFF8C5gqiWyPu5Zm7HsbV1h5xG6A-jhi3cr04Ybg1VzzgQC3t4DYvgx2jSYdRijx_4NFQyNZcHkX1ULWJXzTUBY1btUmXOuFReUUI2q03-ocNW2d1XwtnEYP0h4v0-oYkgp2uahcErMdgjNdgjNfghR_eZxrw_aP1OHgnd7wcrht9-6_6Ph1KEzPBJTThjjvwEFm-6B</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1428035725</pqid></control><display><type>article</type><title>Propranolol in Use for Treatment of Complex Infant Hemangiomas: Literature Review Regarding Current Guidelines for Preassessment and Standards of Care before Initiation of Therapy</title><source>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</source><source>Wiley Open Access</source><source>PubMed Central</source><creator>Fette, Andreas</creator><contributor>Van der Zee, D. C. ; Pollak, A. ; Vandenplas, Y. ; Y Vandenplas ; D C Van der Zee ; A Pollak</contributor><creatorcontrib>Fette, Andreas ; Van der Zee, D. C. ; Pollak, A. ; Vandenplas, Y. ; Y Vandenplas ; D C Van der Zee ; A Pollak</creatorcontrib><description>In 2008, the positive effects of propranolol on infantile hemangiomas (IH) have been discovered serendipitously by Léauté-Labrèze and her coworkers. Since then, propranolol has been in use in allday clinical practice worldwide for treatment of IH. It even caused some kind of paradigm shift in the overall management of these lesions, though propranolol is still not FDA approved, respectively, in “off-label” use for this indication in the majority of institutions. Thus, the aim of this communication is to evaluate the literature for current evidence regarding guidelines for preassessment and standards of care before initiation of therapy.</description><identifier>ISSN: 2356-6140</identifier><identifier>ISSN: 1537-744X</identifier><identifier>EISSN: 1537-744X</identifier><identifier>DOI: 10.1155/2013/850193</identifier><identifier>PMID: 23766715</identifier><language>eng</language><publisher>Cairo, Egypt: Hindawi Publishing Corporation</publisher><subject>Angiogenesis ; Angiogenesis Inhibitors - adverse effects ; Angiogenesis Inhibitors - therapeutic use ; Antineoplastic Agents - adverse effects ; Antineoplastic Agents - therapeutic use ; Apoptosis ; Cardiac arrhythmia ; Cardiovascular disease ; Child ; Clinical medicine ; Clinical trials ; Diseases ; Dosage and administration ; Drug dosages ; Drug therapy ; Evidence-Based Medicine ; Guideline Adherence - utilization ; Hemangioma - diagnosis ; Hemangioma - drug therapy ; Hemangioma - epidemiology ; Humans ; Infants (Newborn) ; Literature reviews ; Medical Oncology - standards ; Pediatrics - standards ; Practice Guidelines as Topic ; Propranolol - adverse effects ; Propranolol - therapeutic use ; Propranolol hydrochloride ; Review ; Standard of care ; Treatment Outcome ; Tumors</subject><ispartof>TheScientificWorld, 2013-01, Vol.2013 (2013), p.1-9</ispartof><rights>Copyright © 2013 Andreas Fette.</rights><rights>COPYRIGHT 2013 John Wiley &amp; Sons, Inc.</rights><rights>Copyright © 2013 Andreas Fette. This is an open access article distributed under the Creative Commons Attribution License (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. https://creativecommons.org/licenses/by/4.0</rights><rights>Copyright © 2013 Andreas Fette. 2013</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c600t-4847ca3ca12d42e9367901a240bf0a0a4988a701ba6d74fd4e3b67866ae5f0c73</citedby><cites>FETCH-LOGICAL-c600t-4847ca3ca12d42e9367901a240bf0a0a4988a701ba6d74fd4e3b67866ae5f0c73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/1428035725/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/1428035725?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,724,777,781,882,25734,27905,27906,36993,44571,53772,53774,74875</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23766715$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Van der Zee, D. C.</contributor><contributor>Pollak, A.</contributor><contributor>Vandenplas, Y.</contributor><contributor>Y Vandenplas</contributor><contributor>D C Van der Zee</contributor><contributor>A Pollak</contributor><creatorcontrib>Fette, Andreas</creatorcontrib><title>Propranolol in Use for Treatment of Complex Infant Hemangiomas: Literature Review Regarding Current Guidelines for Preassessment and Standards of Care before Initiation of Therapy</title><title>TheScientificWorld</title><addtitle>ScientificWorldJournal</addtitle><description>In 2008, the positive effects of propranolol on infantile hemangiomas (IH) have been discovered serendipitously by Léauté-Labrèze and her coworkers. Since then, propranolol has been in use in allday clinical practice worldwide for treatment of IH. It even caused some kind of paradigm shift in the overall management of these lesions, though propranolol is still not FDA approved, respectively, in “off-label” use for this indication in the majority of institutions. Thus, the aim of this communication is to evaluate the literature for current evidence regarding guidelines for preassessment and standards of care before initiation of therapy.</description><subject>Angiogenesis</subject><subject>Angiogenesis Inhibitors - adverse effects</subject><subject>Angiogenesis Inhibitors - therapeutic use</subject><subject>Antineoplastic Agents - adverse effects</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Apoptosis</subject><subject>Cardiac arrhythmia</subject><subject>Cardiovascular disease</subject><subject>Child</subject><subject>Clinical medicine</subject><subject>Clinical trials</subject><subject>Diseases</subject><subject>Dosage and administration</subject><subject>Drug dosages</subject><subject>Drug therapy</subject><subject>Evidence-Based Medicine</subject><subject>Guideline Adherence - utilization</subject><subject>Hemangioma - diagnosis</subject><subject>Hemangioma - drug therapy</subject><subject>Hemangioma - epidemiology</subject><subject>Humans</subject><subject>Infants (Newborn)</subject><subject>Literature reviews</subject><subject>Medical Oncology - standards</subject><subject>Pediatrics - standards</subject><subject>Practice Guidelines as Topic</subject><subject>Propranolol - adverse effects</subject><subject>Propranolol - therapeutic use</subject><subject>Propranolol hydrochloride</subject><subject>Review</subject><subject>Standard of care</subject><subject>Treatment Outcome</subject><subject>Tumors</subject><issn>2356-6140</issn><issn>1537-744X</issn><issn>1537-744X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNqNkt9rFDEQxxdRbK0--S4LvinX5vfmfBDKoe3BgUWv4FuY3c3u5dhNzmS3tX-X_6Bzd7X2wAcJJGHync93hkyWvabklFIpzxih_ExLQqf8SXZMJS8mhRDfn2bHjEs1UVSQo-xFSmtCuC6ofJ4dMV4ohdfj7NdVDJsIPnShy53Pr5PNmxDzZbQw9NYPeWjyWeg3nf2Zz30DGLm0PfjWhR7Sh3zhBhthGKPNv9obZ2_xaCHWzrf5bIxxi7gYXW07523asa-QnZJNaccHX-ffBtwxKe3cAFmlRaVFRzc4GFzw25flCq02dy-zZw10yb66P0-y68-flrPLyeLLxXx2vphUipBhIrQoKuAVUFYLZqdcFVNCgQlSNgQIiKnWUBBagqoL0dTC8lIVWimwsiFVwU-y-Z5bB1ibTXQ9xDsTwJldIMTWQBxc1VmjqZxqrjXhRSUqIkspQTFF8C5gqiWyPu5Zm7HsbV1h5xG6A-jhi3cr04Ybg1VzzgQC3t4DYvgx2jSYdRijx_4NFQyNZcHkX1ULWJXzTUBY1btUmXOuFReUUI2q03-ocNW2d1XwtnEYP0h4v0-oYkgp2uahcErMdgjNdgjNfghR_eZxrw_aP1OHgnd7wcrht9-6_6Ph1KEzPBJTThjjvwEFm-6B</recordid><startdate>20130101</startdate><enddate>20130101</enddate><creator>Fette, Andreas</creator><general>Hindawi Publishing Corporation</general><general>John Wiley &amp; Sons, Inc</general><general>Hindawi Limited</general><scope>ADJCN</scope><scope>AHFXO</scope><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7TK</scope><scope>7TM</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>CWDGH</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>RC3</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20130101</creationdate><title>Propranolol in Use for Treatment of Complex Infant Hemangiomas: Literature Review Regarding Current Guidelines for Preassessment and Standards of Care before Initiation of Therapy</title><author>Fette, Andreas</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c600t-4847ca3ca12d42e9367901a240bf0a0a4988a701ba6d74fd4e3b67866ae5f0c73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Angiogenesis</topic><topic>Angiogenesis Inhibitors - adverse effects</topic><topic>Angiogenesis Inhibitors - therapeutic use</topic><topic>Antineoplastic Agents - adverse effects</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Apoptosis</topic><topic>Cardiac arrhythmia</topic><topic>Cardiovascular disease</topic><topic>Child</topic><topic>Clinical medicine</topic><topic>Clinical trials</topic><topic>Diseases</topic><topic>Dosage and administration</topic><topic>Drug dosages</topic><topic>Drug therapy</topic><topic>Evidence-Based Medicine</topic><topic>Guideline Adherence - utilization</topic><topic>Hemangioma - diagnosis</topic><topic>Hemangioma - drug therapy</topic><topic>Hemangioma - epidemiology</topic><topic>Humans</topic><topic>Infants (Newborn)</topic><topic>Literature reviews</topic><topic>Medical Oncology - standards</topic><topic>Pediatrics - standards</topic><topic>Practice Guidelines as Topic</topic><topic>Propranolol - adverse effects</topic><topic>Propranolol - therapeutic use</topic><topic>Propranolol hydrochloride</topic><topic>Review</topic><topic>Standard of care</topic><topic>Treatment Outcome</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fette, Andreas</creatorcontrib><collection>الدوريات العلمية والإحصائية - e-Marefa Academic and Statistical Periodicals</collection><collection>معرفة - المحتوى العربي الأكاديمي المتكامل - e-Marefa Academic Complete</collection><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health Medical collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central</collection><collection>Advanced Technologies &amp; Aerospace Collection</collection><collection>Agricultural &amp; Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>Middle East &amp; Africa Database</collection><collection>ProQuest Central</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>SciTech Premium Collection (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Agricultural Science Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Advanced Technologies &amp; Aerospace Database</collection><collection>ProQuest Advanced Technologies &amp; Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>Genetics Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>TheScientificWorld</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fette, Andreas</au><au>Van der Zee, D. C.</au><au>Pollak, A.</au><au>Vandenplas, Y.</au><au>Y Vandenplas</au><au>D C Van der Zee</au><au>A Pollak</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Propranolol in Use for Treatment of Complex Infant Hemangiomas: Literature Review Regarding Current Guidelines for Preassessment and Standards of Care before Initiation of Therapy</atitle><jtitle>TheScientificWorld</jtitle><addtitle>ScientificWorldJournal</addtitle><date>2013-01-01</date><risdate>2013</risdate><volume>2013</volume><issue>2013</issue><spage>1</spage><epage>9</epage><pages>1-9</pages><issn>2356-6140</issn><issn>1537-744X</issn><eissn>1537-744X</eissn><abstract>In 2008, the positive effects of propranolol on infantile hemangiomas (IH) have been discovered serendipitously by Léauté-Labrèze and her coworkers. Since then, propranolol has been in use in allday clinical practice worldwide for treatment of IH. It even caused some kind of paradigm shift in the overall management of these lesions, though propranolol is still not FDA approved, respectively, in “off-label” use for this indication in the majority of institutions. Thus, the aim of this communication is to evaluate the literature for current evidence regarding guidelines for preassessment and standards of care before initiation of therapy.</abstract><cop>Cairo, Egypt</cop><pub>Hindawi Publishing Corporation</pub><pmid>23766715</pmid><doi>10.1155/2013/850193</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2356-6140
ispartof TheScientificWorld, 2013-01, Vol.2013 (2013), p.1-9
issn 2356-6140
1537-744X
1537-744X
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_81598388037c4c05b55a62604c04a985
source Publicly Available Content Database (Proquest) (PQ_SDU_P3); Wiley Open Access; PubMed Central
subjects Angiogenesis
Angiogenesis Inhibitors - adverse effects
Angiogenesis Inhibitors - therapeutic use
Antineoplastic Agents - adverse effects
Antineoplastic Agents - therapeutic use
Apoptosis
Cardiac arrhythmia
Cardiovascular disease
Child
Clinical medicine
Clinical trials
Diseases
Dosage and administration
Drug dosages
Drug therapy
Evidence-Based Medicine
Guideline Adherence - utilization
Hemangioma - diagnosis
Hemangioma - drug therapy
Hemangioma - epidemiology
Humans
Infants (Newborn)
Literature reviews
Medical Oncology - standards
Pediatrics - standards
Practice Guidelines as Topic
Propranolol - adverse effects
Propranolol - therapeutic use
Propranolol hydrochloride
Review
Standard of care
Treatment Outcome
Tumors
title Propranolol in Use for Treatment of Complex Infant Hemangiomas: Literature Review Regarding Current Guidelines for Preassessment and Standards of Care before Initiation of Therapy
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T13%3A06%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Propranolol%20in%20Use%20for%20Treatment%20of%20Complex%20Infant%20Hemangiomas:%20Literature%20Review%20Regarding%20Current%20Guidelines%20for%20Preassessment%20and%20Standards%20of%20Care%20before%20Initiation%20of%20Therapy&rft.jtitle=TheScientificWorld&rft.au=Fette,%20Andreas&rft.date=2013-01-01&rft.volume=2013&rft.issue=2013&rft.spage=1&rft.epage=9&rft.pages=1-9&rft.issn=2356-6140&rft.eissn=1537-744X&rft_id=info:doi/10.1155/2013/850193&rft_dat=%3Cgale_doaj_%3EA386341018%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c600t-4847ca3ca12d42e9367901a240bf0a0a4988a701ba6d74fd4e3b67866ae5f0c73%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1428035725&rft_id=info:pmid/23766715&rft_galeid=A386341018&rfr_iscdi=true